Tbio | Protein S100-A2 |
May function as calcium sensor and modulator, contributing to cellular calcium signaling. May function by interacting with other proteins, such as TPR-containing proteins, and indirectly play a role in many physiological processes. May also play a role in suppressing tumor cell growth.
The protein encoded by this gene is a member of the S100 family of proteins containing 2 EF-hand calcium-binding motifs. S100 proteins are localized in the cytoplasm and/or nucleus of a wide range of cells, and involved in the regulation of a number of cellular processes such as cell cycle progression and differentiation. S100 genes include at least 13 members which are located as a cluster on chromosome 1q21. This protein may have a tumor suppressor function. Chromosomal rearrangements and altered expression of this gene have been implicated in breast cancer. [provided by RefSeq, Jul 2008]
The protein encoded by this gene is a member of the S100 family of proteins containing 2 EF-hand calcium-binding motifs. S100 proteins are localized in the cytoplasm and/or nucleus of a wide range of cells, and involved in the regulation of a number of cellular processes such as cell cycle progression and differentiation. S100 genes include at least 13 members which are located as a cluster on chromosome 1q21. This protein may have a tumor suppressor function. Chromosomal rearrangements and altered expression of this gene have been implicated in breast cancer. [provided by RefSeq, Jul 2008]
Comments
Disease | log2 FC | p |
---|---|---|
malignant mesothelioma | -1.300 | 0.000 |
esophageal adenocarcinoma | -3.800 | 0.032 |
psoriasis | 2.300 | 0.000 |
posterior fossa group A ependymoma | 2.300 | 0.000 |
glioblastoma | 1.700 | 0.000 |
atypical teratoid / rhabdoid tumor | 1.400 | 0.000 |
medulloblastoma, large-cell | 1.100 | 0.023 |
Atopic dermatitis | 1.500 | 0.000 |
tuberculosis and treatment for 3 months | -1.200 | 0.000 |
non-small cell lung cancer | 4.841 | 0.000 |
colon cancer | 3.500 | 0.000 |
ulcerative colitis | 1.500 | 0.000 |
pancreatic cancer | 2.000 | 0.001 |
adult high grade glioma | 1.500 | 0.004 |
subependymal giant cell astrocytoma | 1.098 | 0.015 |
lung adenocarcinoma | 2.500 | 0.000 |
nasopharyngeal carcinoma | -1.700 | 0.021 |
spina bifida | -2.475 | 0.049 |
Breast cancer | -1.300 | 0.007 |
ductal carcinoma in situ | 2.300 | 0.006 |
ovarian cancer | 3.100 | 0.000 |
Species | Source |
---|---|
Chimp | OMA EggNOG |
Macaque | OMA EggNOG |
Dog | OMA EggNOG Inparanoid |
Cow | OMA EggNOG Inparanoid |
Platypus | OMA EggNOG Inparanoid |
PMID | Text |
---|---|
25999659 | Data show higher expression level of S100A2 in high-invasive cholangiocarcinoma Cell Line suggesting it as potential marker of tumor progression and novel therapeutic target. |
25874882 | Our investigation complements the current understanding of laryngeal cancer progression. Furthermore, this study supports the concept that enhanced expression of S100A2 may be a promising strategy in developing novel cancer therapeutic drugs. |
25591983 | The potential of cytoplasmic S100A2 overexpression as a predictor of recurrence risk in oral squamous cell carcinoma patients. |
24556685 | These data demonstrate the importance of S100A2 downstream of the BRCA1/DeltaNp63 signalling axis in modulating transcriptional responses and enforcing growth control mechanisms through destabilisation of mutant p53. |
24318973 | loss of S100A2 expression contributes to Ggastric cancer development and progression. |
23996929 | S100A2 protumorigenic actions and its involvement in TGF-beta-mediated cancer cell invasion and epithelial-mesenchymal transition. |
23726265 | Data indicate that S100A2 expression predicts longer disease-free survival (DFS) and overall survival (OS) in patients treated with adjuvant therapy and should be evaluated as a predictive biomarker. |
23621473 | Expression of S100A2 in cholangiocarcinoma cells significantly correlated with the histological grade, lymph node metastasis, clinical stage, and a poor survival rate of the patients. Thus it is a strong tumor marker for the cancer. |
23344957 | Data indicate S100A2 and S100P proteins as novel Ca2+-dependent regulators of the CHIP-proteasome pathway. |
23337980 | In conclusion, data from the present study demonstrated that loss of S100A2 expression contributes to gastric cancer development and progression |
More... |
PMID | Year | Title |
---|---|---|
25999659 | 2015 | Comparative Proteomic Analysis of Human Cholangiocarcinoma Cell Lines: S100A2 as a Potential Candidate Protein Inducer of Invasion. |
25874882 | 2015 | iTRAQ-based quantitative proteomic analysis on S100 calcium binding protein A2 in metastasis of laryngeal cancer. |
25591983 | 2015 | Prognostic significance of cytoplasmic S100A2 overexpression in oral cancer patients. |
25416956 | 2014 | A proteome-scale map of the human interactome network. |
24556685 | 2014 | S100A2 is a BRCA1/p63 coregulated tumour suppressor gene with roles in the regulation of mutant p53 stability. |
24318973 | 2014 | Clinical significance of S100A2 expression in gastric cancer. |
23996929 | 2014 | Protumorigenic actions of S100A2 involve regulation of PI3/Akt signaling and functional interaction with Smad3. |
23726265 | 2013 | S100A2 is a predictive biomarker of adjuvant therapy benefit in pancreatic adenocarcinoma. |
23621473 | 2013 | Clinicopathological significance of S100 protein expression in cholangiocarcinoma. |
23344957 | 2013 | Ca2+/S100 proteins act as upstream regulators of the chaperone-associated ubiquitin ligase CHIP (C terminus of Hsc70-interacting protein). |
More... |